Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Panel Concludes Novartis Systematically Involved in Diovan Trials: Report
March 28, 2014
- Drug-Induced Hypersensitivity Syndrome to Be Added to List of Clinically Significant Adverse Reactions for E Keppra: MHLW
March 28, 2014
- FY2014 Medical Fee Revision Expected to Shift Outpatient Care Functions from Large Hospitals to Smaller Hospitals and Clinics, Alter Patient Behavior and Prescription Patterns
March 28, 2014
- PMDA Floats New Advisory Service on Drug Makers’ Development Plans
March 27, 2014
- PMDA Announces Increase in Face-to-Face Consultation Fees in Response to Upcoming Hike in Consumption Tax
March 27, 2014
- PMDA Publishes RMP for Regpara
March 27, 2014
- Dr Tatsuya Kondo Reappointed as Chief Executive of PMDA
March 26, 2014
- MHLW Approves 37 Products, 4 New SGLT-2 Products OK’ed
March 25, 2014
- MHLW to Disclose Names of Wholesalers Abusing Penalty for Low Price-Settlement Rates
March 25, 2014
- Extra Market Drug Price Survey Focal Point of Discussions towards FY2015 Tax Hike: Official
March 20, 2014
- MHLW to Set Rules on OTC Switching of Diagnostics This Year
March 20, 2014
- MHLW to Draft Rules for Approval of Switch OTC Diagnostics in Meetings Open to the Public: Regulatory Reform Council
March 19, 2014
- MHLW OKs Additional Indications for Votrient, 2 Other Drugs
March 18, 2014
- FY2014 Reform to Strengthen Restrictions on Prescription of Multiple Psychotropic Drugs; Measures to Be Taken in Two Consecutive Reforms Due to Lack of Improvements
March 18, 2014
- PMDA to Up Review Fees for Generics, OTCs, Diagnostics in November
March 17, 2014
- Rules for Approval of Switch OTC Diagnostics to Be Finalized by PAFSC Committee by End of Year: PFSB Director General
March 17, 2014
- Eligibility for Key Pricing Premium Up for Discussion: Govt
March 17, 2014
- Opposition Lawmaker Raps Favorable Treatment for Special Zones in Mixed Healthcare
March 14, 2014
- Chuikyo Approves Promotion of Mixed Healthcare in National Strategic Special Zones, Reduction of Review Period by Half
March 14, 2014
- Committee for Assessment of Advanced Healthcare Services Holds 1st Meeting to Expedite Off-label Use of Anticancer Drugs under Senshin-iryo B program
March 13, 2014
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…